Pharmaceutical News

RSS

AHRQ: Average annual prescription drug expenses for children with asthma have doubled

The percentage of American children treated for asthma increased while their annual drug expenses more than doubled over a 10-year period, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

30 Jul 2011

LA Times: Robots and pharmacies

At Molina Medical Group clinics in Southern California, a vending machine rather than a pharmacist dispenses prescription drugs. Molina officials say the machines make life simpler for patients, but their use has drawn objections from some pharmacists.

30 Jul 2011

Lupin, Lilly partner to promote and distribute Huminsulin products in India and Nepal

Eli Lilly India and Lupin Limited today announced they have entered into a strategic collaboration to promote and distribute Lilly's Huminsulin range of products, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, Huminsulin 30/70 and Humapen Ergo II.

30 Jul 2011

Humira defect lawyers file lawsuit against Abbott in Texas state court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

30 Jul 2011

Pharmalucence selects Bosch to provide isolated filling line for Billerica production facility

Pharmalucence, Inc. has selected Robert Bosch Packaging Technology, Inc. to provide a state-of-the-art isolated pharmaceutical filling line for the new Pharmalucence production facility being constructed in Billerica, MA.

30 Jul 2011

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Pfizer Inc today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company's supplemental Biologics License Application (sBLA) for use of Prevnar 13, in adults aged 50 and older.

30 Jul 2011

WARFARIN Study initiated to assess utility of genetic testing to reduce warfarin-related adverse events

Iverson Genetic Diagnostics, Inc. announced that the WARFARIN Study was initiated at Colorado Heart & Vascular, P.C. in Denver and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

30 Jul 2011

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of ORENCIA (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis.

30 Jul 2011

Researchers examine drug that has potential to stop Parkinson's progression

Researchers from Michigan State University's College of Human Medicine, Van Andel Research Institute and the Translational Genomics Research Institute are investigating a drug that has the potential to not only alleviate Parkinson's symptoms but also halt the disease's progression.

30 Jul 2011

CJ, RaQualia sign license agreement to develop and commercialize RQ-00000010 Partial Agonist

RaQualia Pharma Inc. today announced the signing of a license agreement with CJ CheilJedang Co. (CJ), granting CJ exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 Partial Agonist in Korea, China, Taiwan, India and Southeast Asia.

30 Jul 2011

FDA approves Lannett's ANDA for Phentermine Resin Extended-Release Capsules

Lannett Company, Inc. today announced the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for Phentermine Resin Extended-Release Capsules, 15 mg and 30 mg, representing the fourth product approval the company has received in the last five weeks.

29 Jul 2011

Cadence confirms FDA dosing recommendations for OFIRMEV

Cadence Pharmaceuticals, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.

29 Jul 2011

Pew director issues statement on Prescription Drug User Fee Act hearing

Allan Coukell, director of medical programs for the Pew Health Group, issued the following statement today on a U.S. Senate Health, Education, Labor & Pensions Committee hearing, "FDA User Fees: Advancing Public Health."

29 Jul 2011

New tool can effectively determine likelihood of drugs in the environment

Most synthetic chemical products used in consumer goods end up unchanged in the environment. Given the risks this could pose for the environment and human health, researchers from the Autonomous University of Barcelona (UAB) have developed a new tool to effectively predict what will happen to current and future pharmaceutical products.

29 Jul 2011

Book examines impact of new racial science

In 2005, the Food and Drug Administration approved a drug called BiDil as a therapy for heart failure specifically for African-American patients, claiming in a press release that this was a step toward personalized medicine.

29 Jul 2011

Ivabradine effective in reducing risk of cardiac fibrosis, diastolic heart failure

The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure and cardiac fibrosis.

29 Jul 2011

NIH selects Viamet's novel antifungal compound for inclusion in the TRND program

Viamet Pharmaceuticals, Inc. announced today that one of its novel antifungal compounds has been selected for inclusion in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program.

29 Jul 2011

FDA issues Refusal to File letter for Eisai's perampanel NDA to treat partial-onset seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy which was submitted in May 2011.

29 Jul 2011

BTI's IPOXYN data on traumatic shock and ischemia to be presented at XIIIth MGH symposium

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today that experiments performed in the laboratory of Massachusetts General Hospital (MGH) faculty member Warren M. Zapol, MD, Emeritus Anesthetist-in-Chief and Director of the MGH Anesthesia Center for Critical Care Research, on BTI's new oxygen carrier for traumatic shock and ischemia, IPOXYNTM, will be presented at the "XIII International Symposium on Blood Substitutes and Oxygen Therapeutics" to be held July 27th-29th at MGH.

29 Jul 2011

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

Pharmaceutical News

AHRQ: Average annual prescription drug expenses for children with asthma have doubled

LA Times: Robots and pharmacies

Lupin, Lilly partner to promote and distribute Huminsulin products in India and Nepal

Humira defect lawyers file lawsuit against Abbott in Texas state court

Pharmalucence selects Bosch to provide isolated filling line for Billerica production facility

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

WARFARIN Study initiated to assess utility of genetic testing to reduce warfarin-related adverse events

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Researchers examine drug that has potential to stop Parkinson's progression

CJ, RaQualia sign license agreement to develop and commercialize RQ-00000010 Partial Agonist

FDA approves Lannett's ANDA for Phentermine Resin Extended-Release Capsules

Cadence confirms FDA dosing recommendations for OFIRMEV

Pew director issues statement on Prescription Drug User Fee Act hearing

New tool can effectively determine likelihood of drugs in the environment

Book examines impact of new racial science

Ivabradine effective in reducing risk of cardiac fibrosis, diastolic heart failure

NIH selects Viamet's novel antifungal compound for inclusion in the TRND program

FDA issues Refusal to File letter for Eisai's perampanel NDA to treat partial-onset seizures

BTI's IPOXYN data on traumatic shock and ischemia to be presented at XIIIth MGH symposium

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News